- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00337246
Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) With or Without Rituximab in Previously Treated Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving combination chemotherapy together with rituximab may kill more cancer cells. It is not yet known whether giving combination chemotherapy together with rituximab is more effective than combination chemotherapy alone in treating chronic lymphocytic leukemia.
PURPOSE: This randomized phase II trial is studying how well giving combination chemotherapy with or without rituximab works in treating patients with previously treated chronic lymphocytic leukemia.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
OBJECTIVES:
Primary
- Assess the efficacy and safety of fludarabine, cyclophosphamide, and mitoxantrone hydrochloride with or without rituximab in patients with previously treated chronic lymphocytic leukemia.
- Determine the overall response rate, defined as complete or partial remission, in these patients.
Secondary
- Determine the proportion of patients with undetectable minimal residual disease.
- Determine the 2-year progression-free survival of these patients.
- Determine the 2-year overall survival of these patients.
- Determine the toxicity of this regimen.
OUTLINE: This is a randomized, controlled, open-label, parallel group, multicenter study. Patients are stratified according to prior treatment with fludarabine (refractory vs not refractory or naive). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral fludarabine* and oral cyclophosphamide* on days 1-5 and mitoxantrone hydrochloride IV on day 1.
- Arm II: Patients receive fludarabine*, cyclophosphamide*, and mitoxantrone hydrochloride as in arm I. Patients also receive rituximab IV on day 1.
NOTE: *If the oral regimen is not tolerated, patients may receive fludarabine IV and cyclophosphamide IV on days 1-3.
Treatment in both arms repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for 3 years.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 56 patients will be accrued for this study.
Type d'étude
Inscription (Anticipé)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
England
-
Birmingham, England, Royaume-Uni, B9 5SS
- Birmingham Heartlands Hospital
-
Blackpool, England, Royaume-Uni, FY3 8NR
- Blackpool Victoria Hospital
-
Canterbury, England, Royaume-Uni, CT2 7NR
- Kent and Canterbury Hospital
-
Carshalton, England, Royaume-Uni, SM5 1AA
- St Helier Hospital
-
Dartford Kent, England, Royaume-Uni, DA2 8DA
- Darent Valley Hospital
-
Gillingham Kent, England, Royaume-Uni, ME7 5NY
- Medway Maritime Hospital
-
Leeds, England, Royaume-Uni, LS1 3EX
- Leeds General Infirmary at Leeds Teaching Hospital NHS Trust
-
Leicester, England, Royaume-Uni, LE1 5WW
- Leicester Royal Infirmary
-
Liverpool, England, Royaume-Uni, L7 8XP
- Royal Liverpool and Broadgreen Hospitals NHS Trust
-
Maidstone, England, Royaume-Uni, ME16 9QQ
- Maidstone Hospital
-
Manchester, England, Royaume-Uni, M20 4BX
- Christie Hospital Nhs Trust
-
Truro, Cornwall, England, Royaume-Uni, TR1 3LJ
- Royal Cornwall Hospital
-
Tunbridge Wells, Kent, England, Royaume-Uni, TN4 8AT
- Kent and Sussex Hospital
-
Wishaw, England, Royaume-Uni, ML2 0DP
- Wishaw General Hospital
-
-
Scotland
-
Airdrie, Scotland, Royaume-Uni, ML6 0JF
- Monklands General Hospital
-
-
Wales
-
Cardiff, Wales, Royaume-Uni, CF14 4XW
- University Hospital of Wales
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
- Diagnosis of chronic lymphocytic leukemia requiring therapy
- Previously treated with ≥ 1 chemotherapeutic regimen
PATIENT CHARACTERISTICS:
- WHO performance status 0-2
- Life expectancy ≥ 12 weeks
- Creatinine clearance ≥ 30 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile female patients must use effective contraception for 4 weeks before, during, and for 6 months after completion of study treatment
- Fertile male patients must use effective contraception during and for 6 months after completion of study treatment
- No history of anaphylaxis after exposure to rat or mouse-derived complementary-determining region (CDR)-grafted humanized monoclonal antibodies
- No toxicity attributable to purine analogues (e.g., autoimmune hemolytic anemia, neurological toxicity, or allergy)
- No active infection
- No other severe (particularly cardiac or pulmonary) diseases or mental disorders that would preclude study participation
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior fludarabine (or other purine analogues) combined with cyclophosphamide and mitoxantrone hydrochloride
- No prior rituximab, either alone or in combination with chemotherapy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Masquage: Aucun (étiquette ouverte)
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
|---|
|
Overall response rate as measured by NCI Response Criteria
|
Mesures de résultats secondaires
Mesure des résultats |
|---|
|
Toxicité
|
|
Survie globale à 2 ans
|
|
Survie sans progression à 2 ans
|
|
Proportion of patients with undetectable minimal residual disease
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Peter Hillmen, MD, Leeds General Infirmary
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système immunitaire
- Tumeurs par type histologique
- Tumeurs
- Troubles lymphoprolifératifs
- Maladies lymphatiques
- Troubles immunoprolifératifs
- Leucémie, cellule B
- Leucémie
- Leucémie lymphocytaire chronique à cellules B
- Leucémie, Lymphoïde
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents du système nerveux périphérique
- Inhibiteurs d'enzymes
- Analgésiques
- Agents du système sensoriel
- Agents antirhumatismaux
- Antimétabolites, Antinéoplasique
- Antimétabolites
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Agents antinéoplasiques, alkylants
- Agents d'alkylation
- Agonistes myéloablatifs
- Inhibiteurs de la topoisomérase II
- Inhibiteurs de la topoisomérase
- Agents antinéoplasiques immunologiques
- Cyclophosphamide
- Rituximab
- Fludarabine
- Phosphate de fludarabine
- Mitoxantrone
Autres numéros d'identification d'étude
- CTRU-NCRI-UKCLL01-FCM/FCM-R
- CDR0000485181 (Identificateur de registre: PDQ (Physician Data Query))
- EU-20626
- ROCHE-NCRI-UKCLL01-FCM/FCM-R
- ISRCTN77546448
- EUDRACT-2004-003982-34
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .